Sign in

Saad Z. Usmani, MD

@szusmani.bsky.social
549 followers 73 following 29 posts

Views are my own.

PostsRepliesMedia
Reposted by Saad Z. Usmani, MD
Memorial Sloan Kettering Cancer Center @mskcancercenter.bsky.social · 29/05/2026
Join MSK's @szusmani.bsky.social at #ASCO26 as he presents final results from the DREAMM-9 study evaluating belantamab mafodotin in combination with BVRd for transplant-ineligible patients with newly diagnosed #MultipleMyeloma. 🕒 Friday, May 29 | 3:45 p.m. CDT Learn more: bit.ly/3PSMIIx
042
Reposted by Saad Z. Usmani, MD
OncLive @onclive.bsky.social · 02/01/2026
From Pakistan to the Front Lines of Multiple Myeloma Research @szusmani.bsky.social @mskcancercenter.bsky.social #oncology #myeloma www.onclive.com/view/from-pa...
onclive.com
From Pakistan to the Front Lines of Multiple Myeloma Research | OncLive
Saad Z. Usmani, MD, MBA, FACP, FASCO, is renowned leader whose work has helped redefine treatment standards and extend the lives of patients worldwide.
021
Reposted by Saad Z. Usmani, MD
American Society of Clinical Oncology @ascocancer.bsky.social · 02/04/2026
Dr. Sumanta Pal of @cityofhope.bsky.social discusses the impact of the groundbreaking AQUILA trial in high-risk smoldering multiple myeloma with @vincentrk.bsky.social of Mayo Clinic & @szusmani.bsky.social of @mskcancercenter.bsky.social on the latest #ASCODailyNews Podcast: bit.ly/41FCEVw
052
Reposted by Saad Z. Usmani, MD
MSK Department of Medicine @mskdeptofmed.bsky.social · 09/12/2025
#ASH25: Our collaborator María-Victoria Mateos will share results of a phase 3 study of teclistamab plus daratumumab for relapsed refractory #multiplemyeloma. #mmsm @mskcancercenter.bsky.social @ash.hematology.org @szusmani.bsky.social TODAY | 8:45 a.m. EST Learn more: bit.ly/3MN6MKr
033
Reposted by Saad Z. Usmani, MD
MSK Department of Medicine @mskdeptofmed.bsky.social · 18/09/2025
Coming up at #IMS25: Dr. Sham Mailankody will share the results of a phase 1 clinical trial of concurrent BCMA and GPRC5D #CARTcells for relapsed/refractory #multiplemyeloma. 🗓️ Thursday, September 18 | 4:40 p.m. EDT @mskcancercenter.bsky.social @szusmani.bsky.social @myeloma-society.bsky.social
0103
Reposted by Saad Z. Usmani, MD
MSK Department of Medicine @mskdeptofmed.bsky.social · 19/09/2025
Coming up at #IMS25: Join MSK's Myeloma Service Chief @szusmani.bsky.social to learn about current challenges in #multiplemyeloma relapse & future research needed to overcome them. #mmsm 🗓️ Friday, September 19 | 9:40 a.m. EDT @mskcancercenter.bsky.social @myeloma-society.bsky.social
063
Reposted by Saad Z. Usmani, MD
MSK Department of Medicine @mskdeptofmed.bsky.social · 20/09/2025
At #IMS25, Dr. Francesco Maura will present new research on the genomics that define neoplastic transformation in #multiplemyeloma precursor conditions. #mmsm 🗓️ Saturday, September 20 | 9:20 a.m. EDT @mskcancercenter.bsky.social @myeloma-society.bsky.social @szusmani.bsky.social
042
Reposted by Saad Z. Usmani, MD
MSK Department of Medicine @mskdeptofmed.bsky.social · 13/09/2025
MSK is headed to Toronto for #IMS25! Stay tuned for posters and presentations that are advancing #multiplemyeloma research and treatments. #mmsm @mskcancercenter.bsky.social @szusmani.bsky.social @myeloma-society.bsky.social
052
Reposted by Saad Z. Usmani, MD
MSK Department of Medicine @mskdeptofmed.bsky.social · 17/09/2025
MSK experts have arrived at #IMS25! Join Dr. Francesco Maura to learn about genomic drivers of resistance to anti-BCMA immunotherapies in #multiplemyeloma. #mmsm 🗓️ Wednesday, September 17 | 11:10 a.m. EDT @mskcancercenter.bsky.social @szusmani.bsky.social @myeloma-society.bsky.social
042
Reposted by Saad Z. Usmani, MD
MSK Department of Medicine @mskdeptofmed.bsky.social · 17/09/2025
At #IMS25, Dr. Carlyn Tan will share new data on early mortality associated with real-world bispecific antibody therapy for relapsed/refractory #multiplemyeloma. 🗓️ Wednesday, September 17 | 12:14 p.m. EDT @mskcancercenter.bsky.social @szusmani.bsky.social @myeloma-society.bsky.social
052
Reposted by Saad Z. Usmani, MD
OncLive @onclive.bsky.social · 11/09/2025
Sign up to read exclusive expert insights on key abstracts to watch at #IMS25! @szusmani.bsky.social @mskcancercenter.bsky.social @myeloma-society.bsky.social #mmsm www.onclive.com/view/experts...
022
Reposted by Saad Z. Usmani, MD
Memorial Sloan Kettering Cancer Center @mskcancercenter.bsky.social · 02/06/2025
Join Dr. @szusmani.bsky.social as he presents research on "Daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) in patients with newly diagnosed #MM (NDMM): Subgroup analysis of transplant-ineligible (TIE) patients in the phase 3 CEPHEUS study" at #ASCO25. @ascocancer.bsky.social
062
Reposted by Saad Z. Usmani, MD
Memorial Sloan Kettering Cancer Center @mskcancercenter.bsky.social · 02/06/2025
"The phase 3 CEPHEUS trial previously demonstrated improved efficacy outcomes with DVRd vs VRd in patients with TIE or transplant-differed NDMM," shares myeloma specialist @szusmani.bsky.social during his session at #ASCO25. @ascocancer.bsky.social
092
Reposted by Saad Z. Usmani, MD
OncLive @onclive.bsky.social · 02/06/2025
D-VRd Retains Its Role as a Standard of Care for Transplant-Ineligible Multiple Myeloma @ascocancer.bsky.social @mskcancercenter.bsky.social @szusmani.bsky.social #ASCO25 #mmsm www.onclive.com/view/d-vrd-r...
onclive.com
D-VRd Retains Its Role as a Standard of Care for Transplant-Ineligible Multiple Myeloma
D-VRd led to deeper and more durable responses that translated into improved PFS vs VRd alone in transplant-ineligible patients with multiple myeloma.
052
Reposted by Saad Z. Usmani, MD
MSK Department of Medicine @mskdeptofmed.bsky.social · 07/05/2025
Congrats to Mark G. Kris, Kenneth Offit, David G. Pfister, and @szusmani.bsky.social on being inducted into the 13th Giants of Cancer Care® class by @onclive.bsky.social! This award honors leading physicians who are advancing #cancerresearch. @mskcancercenter.bsky.social Learn more: bit.ly/42Ox58M
083
Reposted by Saad Z. Usmani, MD
International Myeloma Foundation @imfmyeloma.bsky.social · 07/03/2025
❤️ Thank you, Dr. Usmani for continuing to support #MyelomaICE!
021
Saad Z. Usmani, MD @szusmani.bsky.social · 07/03/2025
Dear all, putting in a plug for the International Myeloma Foundation Iceland Cycling Expedition 2025 below. Thanks for your generosity last year, many of you contributed to its success. Every donation and any amount counts. @imfmyeloma.bsky.social fundraise.myeloma.org/fundraiser/5...
fundraise.myeloma.org
Iceland Cycling Expedition
{{MetaTags.description}}
153
Reposted by Saad Z. Usmani, MD
Anish Simhal @aksimhal.bsky.social · 21/02/2025
1/ 🚨New research alert! 🚨Our study in Blood Cancer shows that high WEE1 expression is an independent predictor of poor survival in multiple myeloma, with @joedeasy.bsky.social, @malinhultcrantz.bsky.social, @szusmani.bsky.social, and the rest of the @mskcancercenter.bsky.social team! 🧵👇#MyelomaSky
183
Reposted by Saad Z. Usmani, MD
Memorial Sloan Kettering Cancer Center @mskcancercenter.bsky.social · 06/02/2025
NEW in @natmedicine.bsky.social: Results from a phase 3 clinical trial led by MSK's #myeloma specialist & cellular therapist @szusmani.bsky.social. Learn more: www.nature.com/articles/s41...
0125
Saad Z. Usmani, MD @szusmani.bsky.social · 06/02/2025
Quadruplets induction regimens are the established standards of care now in newly diagnosed MM, just out 🎉👇🏽 #MyelomaSky @mskcancercenter.bsky.social @imfmyeloma.bsky.social @themmrf.bsky.social @healthtreeorg.bsky.social www.nature.com/articles/s41...
nature.com
Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS study - Nature Medicine
In the phase 3 CEPHEUS trial, patients with transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma were treated with subcutaneous daratumumab plus bortezomib, lenalidomide and d...
0103
Reposted by Saad Z. Usmani, MD
DrMHB @drmhb.bsky.social · 18/12/2024
Thanks to @szusmani.bsky.social for donating 🙌🏾🙌🏾🙌🏾🥳🥳🥳 to support multiple myeloma cancer research @ give.themmrf.org/fundraiser/5...
give.themmrf.org
2024 MM4MM: Mount Kilimanjaro
{{MetaTags.description}}
031
Reposted by Saad Z. Usmani, MD
MSK Department of Medicine @mskdeptofmed.bsky.social · 10/12/2024
This is your last chance to see incredible research at the #ASH24 poster session today! Don't miss posters by Drs. Gunjan Shah, Carlyn Rose Tan, & Pallawi Torka. @mskcancercenter.bsky.social @szusmani.bsky.social 6-8 p.m. PST buff.ly/3ZLbSey buff.ly/3OOjjeG buff.ly/3Vum0Wv
073
Reposted by Saad Z. Usmani, MD
Memorial Sloan Kettering Cancer Center @mskcancercenter.bsky.social · 08/12/2024
Congratulations to MSK's Dr. Urvi Shah for being awarded the @ash-hematology.bsky.social David M. Goldenberg Clinical Research Training Institute Award for her work on research that shows that a high-fiber, plant-based dietary intervention may delay progression #MGUS/#SMM to #MM. #ASH24 #ASHKudos
0318
Reposted by Saad Z. Usmani, MD
Memorial Sloan Kettering Cancer Center @mskcancercenter.bsky.social · 08/12/2024
Dr. @szusmani.bsky.social presents on “Working with Data Hub Data and Network PIs to Develop Evidence that Changes Practice in Multiple Myeloma: The COSMIC Study as Proof of Concept” that is part of the ASH Research Collaborative Multiple Myeloma Network at @ash-hematology.bsky.social. #ASH24
0156
Saad Z. Usmani, MD @szusmani.bsky.social · 08/12/2024
Please join us now #ASH24 #MyelomaSky ASH RESEARCH COLLABORATIVE MULTIPLE MYELOMA NETWORK: ACCELERATING RESEARCH AND COLLABORATIVE CLINICAL CARE THROUGH REAL-WORLD EVIDENCE GENERATION December 7, 2024, 4:00 p.m. - 5:30 p.m. Marriott Marquis San Diego Marina, Pacific Ballroom Salons 24-26
071
Reposted by Saad Z. Usmani, MD
Memorial Sloan Kettering Cancer Center @mskcancercenter.bsky.social · 07/12/2024
#ASH24: Join myeloma specialist Dr. @szusmani.bsky.social for his presentation on "Working with Data Hub Data and Network PIs to Develop Evidence that Changes Practice in Multiple Myeloma: The COSMIC Study as Proof of Concept" today at 4pm PT at @ash-hematology.bsky.social. bit.ly/49vscmW
063
Reposted by Saad Z. Usmani, MD
MSK Department of Medicine @mskdeptofmed.bsky.social · 07/12/2024
Join Kylee Maclachlan for the presentation "Genomic Complexity Correlates with the Degree of Marrow Independence of Malignant Plasma Cells in the Context of Extramedullary Disease." 2:15 pm PST. #ASH24 @mskcancercenter.bsky.social @szusmani.bsky.social @ash-hematology.bsky.social buff.ly/4f6J3gP
022
Reposted by Saad Z. Usmani, MD
American Society of Hematology @ash.hematology.org · 05/12/2024
☀️ Awaken your inner poet and write your best haiku about #ASH24 or #hematology! That's 3 lines in a 5-7-5 syllable pattern. Post now through Tuesday afternoon and include #ASHaiku. You might get included in a highlights post! 🛑Remember, there's only one H in #ASHaiku! #HemeSky #Hematology
083
Saad Z. Usmani, MD @szusmani.bsky.social · 05/12/2024
and finally, the #ASH24 #MyelomaSky **Basic/Translational Abstracts: 1019 A 1,000-Genome Map for Multiple Myeloma and Its Precursor Stages, and Its Impact on Clinical Outcome ash.confex.com/ash/2024/web...
ash.confex.com
Paper: A 1,000-Genome Map for Multiple Myeloma and Its Precursor Stages, and Its Impact on Clinical Outcome
132
Saad Z. Usmani, MD @szusmani.bsky.social · 05/12/2024
Up next, the #ASH24 #MyelomaSky **Clinical Abstracts - RRMM @ash-hematology.bsky.social 1029 CAR-T Cell Therapy in Advanced Myeloma with EMD In Vivo Imaging and Molecular Monitoring Study (CARAMEL): First Results of Cu-64 Radiolabelled Nanoparticle PET-CT and PET-MRI ash.confex.com/ash/2024/web...
ash.confex.com
Paper: CAR-T Cell Therapy in Advanced Myeloma with Extramedullary Disease – an <em>In Vivo</Em> Imaging and Molecular Monitoring Study (CARAMEL): First Results of Cu-64 Radiolabelled Nanoparticle PET-...
101
Saad Z. Usmani, MD @szusmani.bsky.social · 05/12/2024
Alright #MyelomaSky peeps, here is my best of #ASH24 abstract list, no rank order here. I may add to this list during the meeting based on data we hear in the live meeting @ash-hematology.bsky.social
media.tenor.com
a man in a green elf costume is standing in a room with his mouth open .
ALT: a man in a green elf costume is standing in a room with his mouth open .
252
Reposted by Saad Z. Usmani, MD
Ajay Major, MD, MBA @majorajay.bsky.social · 27/11/2024
cc @rahulbanerjeemd.bsky.social @mtmdphd.bsky.social @myelomateacher.bsky.social @szusmani.bsky.social @oncoalert.bsky.social
021
Reposted by Saad Z. Usmani, MD
Ajay Major, MD, MBA @majorajay.bsky.social · 27/11/2024
The #ASH24 community is really ramping up in the last week before sunny San Diego. Looking forward to a phenomenal annual meeting, y'all! #ASHKudos cc @ash-hematology.bsky.social
173
Reposted by Saad Z. Usmani, MD
Dan Auclair @auclairdan.bsky.social · 05/12/2024
From @szusmani.bsky.social “When entering the field do not aspire to be a ‘top influencer’… aspire to move the field forward, look up to people who have moved the field … everyone can tell fluff from substance… do the right thing for patients” So true! Or else 👇 #MyelomaSky youtu.be/qs5N8otc6bk
youtu.be
penguin slipped🤣#memes #funnycomedy #funnyshorts #pinguinofishing
YouTube video by Mr Kusam
032
Reposted by Saad Z. Usmani, MD
Miguel Perales MD @drmiguelperales.bsky.social · 30/11/2024
ASTCT recently released a special issue of Transplantation and Cellular Therapy dedicated to the latest research, challenges and innovations in chronic #GVHD management. #bmtsm www.astctjournal.org/issue/S2666-...
0145
Reposted by Saad Z. Usmani, MD
Muzaffar Qazilbash @transplantdoc.bsky.social · 04/12/2024
#ASH24 Phase I clinical trial of Anti-BCMA/GPRC5D bispecific CAR T-Cells in RRMM with Extramedullary Disease. N=6, ORR: 100% (CR: 50%) #mmsm #bmtsm ash.confex.com/ash/2024/web...
ash.confex.com
Paper: A Single-Center, Single-Arm, Phase I Clinical Trial of Anti-BCMA/GPRC5D Bispecific CAR T-Cells in Patients with Refractory and Relapsed Multiple Myeloma with Extramedullary Disease
041
Reposted by Saad Z. Usmani, MD
Muzaffar Qazilbash @transplantdoc.bsky.social · 04/12/2024
#ASH24 Phase II trial of Anito-cel in RRMM #mmsm #bmtsm N=58, ORR: 95%, CR: 62%, MRD- 10^-5: 92%, CRS: 84%, no delayed neurotoxicity #mmsm #bmtsm ash.confex.com/ash/2024/web...
ash.confex.com
Paper: Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma: Preliminary Results from the IMMagine-1 Trial
052
Reposted by Saad Z. Usmani, MD
Muzaffar Qazilbash @transplantdoc.bsky.social · 04/12/2024
#ASH24 Cilta-cel vs. SOC in RRMM (1-3 lines), CARTITUDE-4; MRD- update. N=419, median F/U: 33.6 months. >3-fold increase in MRD -ve with cilta-cel #mmsm #bmtsm ash.confex.com/ash/2024/web...
ash.confex.com
Paper: Ciltacabtagene Autoleucel (Cilta-cel) Vs Standard of Care (SoC) in Patients with Lenalidomide (Len)-Refractory Multiple Myeloma (MM) after 1–3 Lines of Therapy: Minimal Residual Disease (MRD) N...
072
Saad Z. Usmani, MD @szusmani.bsky.social · 04/12/2024
This is big news, big lesson for those who will heed the warning!
050
Reposted by Saad Z. Usmani, MD
Gregory Riely @rielymd.bsky.social · 04/12/2024
As we explore more and more HLA-specific immune based therapies, this from MSK in JAMA Onc shows that standard NGS testing can infer HLA genotypes. Other NGS providers have done/can do @adamjschoenfeld.bsky.social @mskcancercenter.bsky.social @davidaggen.bsky.social jamanetwork.com/journals/jam...
jamanetwork.com
Next-Generation Sequencing for HLA Genotype Screening and Matching to HLA-Restricted Therapies
This case series evaluates whether human leukocyte antigen (HLA) genotype could be inferred from standard next-generation sequencing, comparing concordance with confirmatory whole-exome sequencing and...
0105
Reposted by Saad Z. Usmani, MD
Coach Bonnie @coachbon.bsky.social · 04/12/2024
041
Reposted by Saad Z. Usmani, MD
American Society of Hematology @ash.hematology.org · 03/12/2024
📹 Make the most of the ASH Annual Meeting — here's what you need to know before you go! www.youtube.com/watch?v=QGDX... Learn about registration hours and locations, download the #ASH24 app, & preview the virtual platform and the new food guide! 😋🍔Check your email. #HemeSky #Hematology
youtube.com
Know Before You Go: 66th ASH Annual Meeting and Exposition
YouTube video by American Society of Hematology
1217
Reposted by Saad Z. Usmani, MD
Myeloma Society @myeloma-society.bsky.social · 29/09/2024
Don't forget, you can still access #IMS24 meeting content. If you registered for either in-person or virtual, login to the virtual platform to review all recorded sessions. virtual.imsannual.org/login
032
Reposted by Saad Z. Usmani, MD
Myeloma Society @myeloma-society.bsky.social · 25/11/2024
Attention #Myeloma researchers! 🌟 Don't miss out on this fantastic opportunity - apply for the IMS Translational Research Award by Jan 31, 2025! For all the details, click here: ow.ly/ge3s50TXPtt #ResearchGrant
043
Reposted by Saad Z. Usmani, MD
Myeloma Society @myeloma-society.bsky.social · 26/11/2024
Please join us for our Educational Workshop in Johannesburg, South Africa, from February 28 to March 1, 2025! Get ready for engaging lectures and lively roundtable discussions. Don’t miss out—register today! ➡️ bit.ly/4gnDs7X
bit.ly
Educational Workshop Johannesburg, South Africa
031
Reposted by Saad Z. Usmani, MD
Myeloma Society @myeloma-society.bsky.social · 27/11/2024
Calling all young investigators! Are you curious about the @myeloma-society.bsky.social Career Development Award and how it can help your career? Learn more here: ow.ly/4vFx50UcLZj and apply before our January 31 deadline!
043
Reposted by Saad Z. Usmani, MD
Myeloma Society @myeloma-society.bsky.social · 04/12/2024
Registration is now open for the 6th Immune Effector Cell Therapies Workshop from March 28-29 in Boston. Learn more here ➡️ bit.ly/4eaHPlg
bit.ly
6th Immune Effector Cell Therapies in Multiple Myeloma Workshop
032
Saad Z. Usmani, MD @szusmani.bsky.social · 04/12/2024
Heading out for #ASH24, I will be posting my impressions of the data on this platform and see how it goes. #mmsm #BMTsm #lymsm #leusm #CARTsm @themmrf.bsky.social @imfmyeloma.bsky.social @mskcancercenter.bsky.social @drmiguelperales.bsky.social @shematologist.bsky.social
media.tenor.com
a man in a black shirt is standing in front of a sign that says travis
ALT: a man in a black shirt is standing in front of a sign that says travis
2243
Saad Z. Usmani, MD @szusmani.bsky.social · 26/11/2024
Thanks Daniel! We will rotate this meeting between Mayo and MSK - next year in Minneapolis and save-the-date coming soon #MyelomaSky #MMsm
070
Reposted by Saad Z. Usmani, MD
Nikhil Munshi, MD @nikhilmunshi.bsky.social · 23/11/2024
An interesting paper in Blood by Dr. Samur suggesting that the cell that eventually becomes myeloma first acquires extra chromosome in 2nd decade of life and becomes fully hyperdiploid by 3rd. Implication for many cancers. @pedalheadphx.bsky.social @auclairdan.bsky.social @szusmani.bsky.social
3238